Cidara Therapeutics, Inc. announced on October 2, 2025, that it has received an award valued up to $339 million from the Biomedical Advanced Research and Development Authority (BARDA). This multi-year agreement includes a Base contract with Option periods.
The Base period funding of $58 million over 24 months will support the onshoring of CD388 manufacturing to the United States, supplementing the initial commercial supply chain. This initial funding will also facilitate a clinical trial to demonstrate comparability of a higher-concentration formulation and different presentations of CD388, further characterize its activity against pandemic influenza strains, and initiate development of clinical trial protocols for expanded populations.
Option periods, if exercised by the U.S. government, could provide up to an additional $281 million to support further clinical and non-clinical studies of CD388 in specific populations, complementing Cidara's plans for potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). This partnership accelerates domestic supply options for CD388 production and ensures U.S. supply in the event of an influenza pandemic.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.